Creesevita Subcutaneous Injection 10mg, containing burosumab (genetical recombination), is a human monoclonal antibody medication manufactured by Kyowa Kirin. It is approved to treat X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), and is available as a 10mg 1mL 1 bottle with YJ code 3999452A1024.
Creesevita Subcutaneous Injection 10mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →